These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 31076056)

  • 21. The use of biologics in personalized asthma care.
    Watchorn D; Holguin F
    Expert Rev Clin Immunol; 2021 Dec; 17(12):1301-1309. PubMed ID: 34767743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 26. [New drugs for severe asthma].
    Sattler C; Malrin R; Garcia G; Humbert M
    Presse Med; 2016 Nov; 45(11):1043-1055. PubMed ID: 27836376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological treatments for severe asthma.
    Assaf SM; Hanania NA
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
    Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
    Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways.
    Cataldo D; Louis R; Michils A; Peché R; Pilette C; Schleich F; Ninane V; Hanon S
    J Asthma; 2021 Apr; 58(4):448-458. PubMed ID: 31928102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential of biologics for the treatment of asthma.
    Pelaia G; Vatrella A; Maselli R
    Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.
    Chupp G; Lugogo NL; Kline JN; Ferguson GT; Hirsch I; Goldman M; Zangrilli JG; Trudo F
    Ann Allergy Asthma Immunol; 2019 May; 122(5):478-485. PubMed ID: 30802500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the current role of biologics in the management of patients with severe refractory asthma?
    Draikiwicz S; Oppenheimer J
    Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
    Peters MC; Wenzel SE
    Lancet; 2020 Feb; 395(10221):371-383. PubMed ID: 32007172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
    Han D; Lee JK
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.